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Foxp3þ Regulatory T Cells of Psoriasis Patients
Easily Differentiate into IL-17A-Producing Cells
and Are Found in Lesional Skin
H. Jorn Bovenschen1, Peter C. van de Kerkhof1, Piet E. van Erp1, Rob Woestenenk2, Irma Joosten3 and
Hans J.P.M. Koenen3
Psoriasis is an autoimmune-related chronic inflammatory skin disease that is strongly associated with IL-23 and
T helper-17 (Th17) effector cytokines. In addition, CD4þCD25high regulatory T-cell (Treg) function appeared to
be impaired in psoriasis. CD4þCD25highFoxp3þ Tregs are typically considered inhibitors of autoimmune
responses. However, under proinflammatory conditions, Tregs can differentiate into inflammation-associated
Th17 cells—a paradigm shift, with as yet largely unknown consequences for human disease initiation or
progression. Th17 cells are highly proinflammatory T cells that are characterized by IL-17A and IL-22 production
and expression of the transcription factor retinoic acid-related orphan receptor gt (RORgt). We here show that
Tregs of patients with severe psoriasis, as compared with those of healthy controls, have an enhanced
propensity to differentiate into IL-17A-producing cells on ex vivo stimulation. This enhanced Treg differentiation
was linked to unexpectedly high RORgt levels and enhanced loss of Foxp3. Notably, IL-23 boosted this Treg
differentiation process particularly in patients with psoriasis but less so in controls. IL-23 further reduced Foxp3
expression while leaving the high RORgt levels unaffected. The histone/protein deacetylase inhibitor,
Trichostatin-A, prevented Th17 differentiation of Tregs in psoriasis patients. Importantly, IL-17Aþ /Foxp3þ /
CD4þ triple-positive cells were present in skin lesions of patients with severe psoriasis. These data stress the
clinical relevance of Treg differentiation for the perpetuation of chronic inflammatory disease and may pave
novel ways for immunotherapy.
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INTRODUCTION
Several human autoimmune disorders are associated with
pathogenic T helper-17 (Th17) cells (Tesmer et al., 2008) as
well as with dysfunctional regulatory T cells (Tregs;
Brusko et al., 2008). A recent paradigm shift with regard to
T-cell lineage development (Koenen et al., 2008; Yang et al.,
2008b; Ayyoub et al., 2009; Beriou et al., 2009; Voo et al.,
2009; Zhou et al., 2009) may point to a new role for Tregs in
the perpetuation of inflammatory processes, rather than in the
suppression thereof.
Psoriasis is an autoimmune-related chronic inflammatory
skin disease (Nestle et al., 2009). The disease is strongly
associated with the Th17-driving cytokine IL-23 (Nair et al.,
2009) and Th17 cells, which express the transcription factor
retinoic acid-related orphan receptor gt (RORgt; Teunissen
et al., 1998; Wilson et al., 2007; Lowes et al., 2008). Th17
cells produce among others the effector cytokines IL-17A and
IL-22, which may have a prominent pathogenic role in skin
inflammation and the development of psoriatic plaques
(Teunissen et al., 1998; Wilson et al., 2007; Lowes et al.,
2008). Increased numbers of IL-17A- and IL-22-producing
T cells were present in the peripheral blood of psoriasis
patients (Kagami et al., 2010). Psoriasis has also been
associated with impaired suppressive capacity of Tregs
(Sugiyama et al., 2005). Tregs are essential for immune
homeostasis by virtue of their capacity to suppress the
function of other lymphocytes, thereby suppressing immune
responses, inflammation, and tissue destruction. Stable
expression of the Treg master transcription factor, Foxp3, is
crucial for Treg function (Zhou et al., 2009).
Human Th17 cells were shown in vitro to differentiate
from naive or memory CD4þ T cells, dependent on the
presence of the cytokines transforming growth factor-b, IL-1b,
IL-6, IL-21, and IL-23 (Wilson et al., 2007; costa-Rodriguez
et al., 2007; Manel et al., 2008; Volpe et al., 2008; Yang
et al., 2008a). Interestingly, we and others have recently
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demonstrated that CD4þCD25high Foxp3þ Tregs obtained
from healthy individuals can convert into inflammation-
associated Th17 cells (Koenen et al., 2008; Ayyoub et al.,
2009; Beriou et al., 2009; Voo et al., 2009). This Treg
differentiation was further promoted by the proinflammatory
cytokines, such as IL-1b, IL-21, and IL-23 (Koenen et al.,
2008). In mice, the adoptive transfer of differentiated Tregs
led to autoimmunity (Zhou et al., 2009). This brought us to
propose that next to dysfunction of Tregs, differentiation
of Tregs into an inflammatory cell type might very well
contribute to the perpetuation of chronic autoimmunity, such
as psoriasis, in humans.
Here we present data that reveal that differentiated IL-17A-
producing Tregs might have a role in human chronic
inflammatory processes. This is substantiated by the finding
that peripheral-blood-derived Tregs of severe psoriasis
patients easily differentiate into a Th17-associated pheno-
type, in patients this differentiation process appeared to be
very adequately promoted by IL-23. Most importantly,
Foxp3þ IL-17A-producing cells can be found in the lesional
skin of patients with severe psoriasis, and likely contribute to
the perpetuation of immune pathology. This to our knowl-
edge, previously unreported concept may well influence the
choice and the development of future treatment modalities.
RESULTS AND DISCUSSION
Ex vivo-stimulated CD4þCD25high Tregs from patients with
severe psoriasis show enhanced IL-17A production
To examine whether differentiation of Tregs to Th17 can have
a role in human chronic inflammatory disease processes, we
first set out to analyze peripheral blood Tregs from psoriasis
patients. Previously, it was shown that in psoriasis patients,
the suppressor capacity of peripheral blood Tregs was
reduced, whereas their frequency and anergic phenotype
appeared unchanged (Sugiyama et al., 2005). Indeed, we
here show that this holds true for Tregs from patients with
mild (Psoriasis Area and Severity Index 5.1) and severe
(Psoriasis Area and Severity Index 15.8) plaque psoriasis
(Supplementary Figure 1a,b/2a,b online). Next, we studied
the potential of these Tregs to produce the inflammatory
cytokines, such as IL-17A, IL-22, and IFN-g, known to be
involved in the pathogenesis of psoriasis (Teunissen et al.,
1998; Lowes et al., 2008; Nestle et al., 2009). Importantly, all
three cytokines were produced, but in stimulated Tregs from
severe psoriasis patients, we found significantly (Po0.05)
increased amounts of IL-17A in the culture supernatants
as compared with Tregs from healthy controls (Figure 1a).
No significant difference was observed for IFNg or IL-22. In
contrast to Tregs, stimulated CD4þCD25 conventional
T cells of psoriasis patients revealed similar levels of IL-17A,
IL-22, and IFNg as those found for healthy controls
(Figure 1a). These findings suggest that Tregs of severe
psoriasis patients are particularly prone to differentiate into
IL-17A-producing cells. Thus, we sought to investigate in
more depth.
Increased IL-17A production by Tregs from severe psoriasis
patients is the result of enhanced numbers of IL-17A-producing
cells and increased IL-17A expression levels per cell
We evaluated the increased IL-17A-producing capacity of
Tregs from psoriasis patients (Figure 1b) at the single-cell
level using flowcytometry. To this end, CD4þCD45RA-
CD25high Tregs were isolated by high-purity flowcytometric
cell sorting, resulting in 498% Foxp3þ cells that lack
CD127 expression (data not shown). Following ex vivo
stimulation of Tregs from severe psoriasis patients, we found
a significant increase in the percentage of intracellular
IL-17A-producing cells as compared with healthy controls
(mean±SEM; 9.3±2.4%, n¼7; 3.2±0.7%, n¼8, respec-
tively; P¼0.0236; Figure 1b and c). In addition, these cells
produced higher levels of IL-17A on a per cell basis
(fluorescence intensity; 366±68, n¼7 vs. 150±19, n¼ 8,
respectively; P¼ 0.064; Figure 1b and d). The majority
of the cells were IL-17Aþ /IFNg-producing Th17 cells
(Supplementary Figure 3 online).
These findings indicate that highly purified Tregs from
severe psoriasis patient, as compared with healthy controls,
have an increased potential to produce IL-17A following
ex vivo stimulation. Thus, we interpret as an enhanced
propensity of Tregs to differentiate into IL-17A-producing
cells. The Treg population is heterogeneous with respect to
the expression of cell surface markers and the transcription
factor Foxp3, although both Foxp3low- and Foxp3high-expres-
sing Tregs can produce IL-17A, it appeared that within the
Foxp3low population more cells were able to produce IL-17A
(Miyara et al., 2009). Further investigation is needed to reveal
whether the Foxp3low or Foxp3high Tregs are differentiating
into IL-17A-producing cells in psoriasis patients. Importantly,
directly ex vivo isolated Foxp3þTregs did not produce
IL-17A (Figure 2).
This supports our finding that the increased IL-17A
production found in psoriasis patients is truly due to Treg
Figure 1. Ex vivo-stimulated CD4þ CD25high T cells from patients with severe psoriasis show increased IL-17A production. (a) Cytokine production measured
by a Luminex cytokine assay (IL-17A, IFNg) and ELISA (IL-22) in cell culture supernatants of isolated CD4þCD25þ (upper panel) and CD4þCD25 T cells
(lower panel) after 4 days of ex vivo stimulation with anti-CD3/CD28mAb-coated beads. Cells were derived from healthy controls and mild and severe psoriasis
patients. Data show SEM and mean of n¼4–5 controls or patients. (b) Flowcytometry of the intracellular IL-17A production in high-purity cell sorted
CD4þCD45RA-CD25high from healthy controls (upper panel) and severe psoriasis patients (lower panel) on ex vivo stimulation as indicated at the top.
Intracellular IL-17A measurement was performed at day 8 of the cultures after stimulation with phorbol 12-myristate 13-acetate plus ionomycin in the presence
of brefeldin-A. Dot plots show the percentage and mean fluorescence intensity (MFI) of CD3þ IL-17A-producing cells. Representative experiments from n¼ 6–7
controls or patients are shown. (c) Summarized data showing the percentages and (d) mean fluorescence intensity (MFI) of IL-17A-producing cells in sorted
and ex vivo stimulated CD4þCD25high from healthy controls and severe psoriasis patients as shown in b. Each data point represents one separate experiment
conducted with cells obtained from different healthy blood donors or severe psoriasis patients.
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differentiation. Moreover, we excluded the possibility that the
IL-17A-producing cells in our Treg cultures arose from
contaminating CD4þCD25þ effector, memory cells or
CD4þCD25 T –cells, or CD161þ Th17 cell precursors
(Koenen et al., 2008; Ayyoub et al., 2009; Beriou et al., 2009;
Voo et al., 2009; and data not shown). The observation that
Tregs reveal plasticity and have the ability to differentiate into
IL-17-producing cells has more recently been confirmed by
others (Koenen et al., 2008; Ayyoub et al., 2009; Beriou
et al., 2009; Voo et al., 2009).
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Increased Treg differentiation in patients with severe
psoriasis is associated with high expression levels of RORct
and enhanced loss of Foxp3
According to expectation, using flowcytometry, we observed
that IL-17A-producing Tregs derived from severe psoriasis
patients and controls expressed the Th17-associated tran-
scription factor RORgt (Koenen et al., 2008; Ayyoub et al.,
2009; Voo et al., 2009; Figure 3). However, interestingly, we
found that on stimulation, patient-derived IL-17A-producing
Tregs revealed far higher levels of RORgt as compared with
healthy controls. This may explain, at least in part, the
increased Treg differentiation rate of patient-derived Tregs.
Foxp3 can directly bind to RORgt and antagonize Th17
differentiation of T cells (Zhou et al., 2008; Yang et al.,
2008b). The balance between Foxp3 and RORgt may
determine whether a Tregs or Th17 differentiation program
will be induced (Yang et al., 2008b). In vivo in mice,
inflammatory conditions were shown to induce loss of Foxp3
expression by Tregs (Yang et al., 2008b; Zhou et al., 2009)
and result in proinflammatory effector cytokine production
(IL-17A, IFNg) by these cells (Zhou et al., 2009). In our
previous work, we showed that human Foxp3þ Tregs that
convert into IL-17A-producing cells gradually lost expression
of Foxp3 (Koenen et al., 2008): early after stimulation the
Tregs co-expressed Foxp3 and IL-17A, whereas later in time
Foxp3 expression was progressively lost. This reveals that,
Tregs that differentiate into an IL-17A-producing phenotype
pass through a Foxp3/IL-17A-double-positive stage. Having
established that on ex vivo stimulation, Tregs from severe
psoriasis patients showed both increased RORgt and IL-17A
levels (Figures 1 and 3), we wondered whether this feature
was indeed also associated with progressive loss of Foxp3
expression. Following stimulation of Foxp3þ Tregs from
severe psoriasis patients, we found that significantly more
cells lost expression of Foxp3 as compared with healthy
controls (% Foxp3-positive cells: 47.8±2.2%, n¼ 7 vs.
62.6±1.9%, n¼ 8, respectively; P¼ 0.002; Figure 4a and b).
In line with our previous observations (Koenen et al., 2008),
we found cells that were positive for both Foxp3 and IL-17A,
as well as cells that had already lost Foxp3 expression
(Figure 4c).
IL-23 strongly boosts Treg differentiation in psoriasis patients,
which is associated with enhanced loss of Foxp3
Interestingly, supplementation of IL-23, a cytokine that is
strongly associated with psoriasis and present in psoriatic
plaques (Nair et al., 2009), greatly promoted the percentage
of IL-17A-producing Tregs, particularly in psoriasis patients
(17.0±2.6%, n¼ 6 patients vs. 6.3±1.6%, n¼8 healthy
controls, respectively; P¼ 0.0006; Figures 1b and c and 4c).
In psoriasis patients, this was accompanied by the enhanced
loss of Foxp3 expression (Figure 4a, b and c), whereas
the increased RORgt levels were maintained (Figure 3).
Genome-wide association studies have indicated the IL-23
receptor (IL-23R) locus as a susceptibility gene in psoriasis
(Nair et al., 2009). We reasoned that increased expression of
the IL-23R might be an alternative possibility of why Tregs
from psoriasis patients could be more prone to differentiate
into IL-17A-producing cells. However, we did not observe an
increased expression levels of the IL-23R or increased
numbers of IL-23R-expressing CD25high/Foxp3 cells, as these
were similar for both patients and healthy controls. Therefore,
the increased response of the patient Tregs toward IL-23 was
not due to the increased expression of the IL-23R.
Although IL-1b supplementation increased IL-17A produc-
tion in Tregs from both psoriasis patients and healthy controls
(Figures 1b and c and 4c), this, in contrast to IL-23, was
not accompanied by a similar drop in Foxp3 levels (Figure 4a,
b and c).
Histone/protein deacetylases regulate chromatin remodel-
ing, gene expression and the functions of many transcription
factors, and non-histone proteins. Acetylation of histones
leads to an open chromatin structure, which is permissive for
the initiation of gene transcription and expression. Histone/
protein deacetylase inhibition by Trichostatin-A (TSA)
increased histone acetylation resulting in increased
Foxp3 protein expression in mouse Tregs (Tao et al., 2007).
In human Tregs, TSA prevented the production of IL-17A
and sustained Foxp3 expression (Koenen et al., 2008).
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Figure 2. Lack of intracellular IL-17A production by freshly isolated
Foxp3þ CD4þ cells. (a) Flowcytometry of the intracellular IL-17A
production and Foxp3 expression in isolated CD4þ cells from healthy
controls (left panel) and severe psoriasis patients (right panel) directly after
isolation and following stimulation of phorbol 12-myristate 13-acetate plus
ionomycin in the presence of brefeldin A. Dot plots show Foxp3 (x-axis) and
IL-17 (y-axis) expression. Percentages of IL-17-producing cells are indicated
in the dot plots. Representative experiments are shown. (b) Summarized data
showing the percentage of IL-17-producing cells (y-axis). Each data point
represents one separate experiment conducted with cells obtained from
different healthy blood donors or severe psoriasis patients.
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Importantly, in psoriasis patients, the enhanced differentia-
tion of Tregs into a Th17-like phenotype could be inhibited
by TSA (Figure 4d), which might be of interest for the
development of new therapeutic modalities.
IL-17A-producing Foxp3þ CD4þ T cells are present in the
dermis of the lesional skin of severe psoriatic patients
To date, we demonstrated that Tregs isolated from the
peripheral blood of severe psoriasis patients have an
enhanced capacity to differentiate into IL-17A-producing
cells. A role for these cells in the perpetuation of the local
inflammatory process would be likely if we could detect such
cells directly at the site of active inflammation. Thus, we
assessed the presence of Foxp3/IL-17A-double-positive cells
in the lesional skin of patients with severe psoriasis using
immunohistochemistry. Notably, CD4þ cells positive for
both Foxp3 and IL-17A were clearly present in the psoriatic
dermis (Figure 5a and b), but absent in either lesional
epidermis or non-lesional skin (data not shown). We also
found CD4þ IL-17A-producing cells that lacked Foxp3
expression (Figure 5a and b).
Collectively, our current work indicates that Foxp3þ
Tregs in severe psoriatic patients have an enhanced
propensity to lose Foxp3 expression, while maintaining
a high level of RORgt expression, all in favor of a high
RORgt:Foxp3 ratio to promote the induction of a proin-
flammatory IL-17A transcription program. The cytokine IL-23
strongly drives this process. Clinical trials with monoclonal
antibodies that target IL-12p40 subunit, which is shared by
both IL-23 and IL-12, have shown high efficacy in psoriasis
(Griffiths et al., 2010). Limiting the IL-23-driven differentia-
tion program of Tregs may explain at least part of this success.
Importantly, the presence of Foxp3þ IL-17A-producing
cells in the proinflammatory environment of the psoriatic
dermis suggests that the conversion of Tregs into IL-17A-
producing cells might take place in vivo in humans. This, in
turn, might inadvertently contribute to the perpetuation of
the inflammatory condition. These findings, together with
the recent observations in mouse models, which show that
the differentiation of Tregs into pathogenic-cytokine-secreting
cells is able to induce autoimmunity (Zhou et al., 2009), and
this finding might provide to our knowledge, previously
unreported mechanistic understanding of the process that
drives chronic autoimmune inflammation.
MATERIALS AND METHODS
Psoriasis patients and healthy volunteers
Patients with mild-to-moderate psoriasis (Psoriasis Area and Severity
IndexB5), severe psoriasis (Psoriasis Area and Severity IndexX15),
and healthy volunteers were recruited according to the Declaration
of Helsinki and following approval of medical ethics committee of
the Radboud University Medical Centre. After given informed
consent, 100ml of peripheral blood was collected. Punch biopsies
(4mm) were taken from the center of a psoriatic lesion and from
uninvolved skin on local anesthesia. Healthy controls did not have a
positive (family) history of psoriasis or other autoimmune or skin
diseases. Patients did not use any topical treatment for at least 1
month and were naive to photo(chemo)therapy or systemic
treatment for psoriasis. Furthermore, they were otherwise healthy
and did not use any other systemic medication.
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Figure 3. Ex vivo-stimulated CD4þ CD25high T cells from patients with severe psoriasis show increased retinoic acid-related orphan receptor ct (RORct)
expression levels. Flowcytometry of intracellular IL-17A and RORgt expression in high-purity cell sorted CD4þCD45RA-CD25high from healthy controls
(top panel) and severe psoriasis patients (lower panel) on stimulation as described under Figure 1. Dot plots show the percentage of IL-17A-producing RORgtþ
double-positive cells and RORgt expression levels (mean fluorescence intensity (MFI)). Data are representative of three separate experiments conducted with
cells obtained from different healthy blood donors or severe psoriasis patients.
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Cell isolation and culture of cells
Peripheral blood mononuclear cells were isolated by density
gradient centrifugation (Lymphoprep; Nycomed Pharma, Oslo,
Norway). CD4þ T cells were purified from peripheral blood
mononuclear cells by negative selection as described previously
(Koenen et al., 2008) or by positive selection using the magnetic-
activated cell sorting CD4-beads (Miltenyi-Biotec, Bergisch-
Gladbach, Germany) as indicated by the manufacturer. To isolate
CD4þCD45RA-CD25high Tregs, purified CD4þ T cells were
labeled with CD4(MT310)FITC (Dako, Glostrup, Denmark),
CD25(MA251)PE (BD-Biosciences, Erembodegem, Belgium),
CD45RA(2H4)ECD (Beckman-Coulter, Mijdrecht, the Netherlands),
thereafter CD4þCD25highCD45RA cells (Tregs) were isolated by
high-purity flowcytometric cell sorting using an Altra cell sorter
(Beckman-Coulter). A re-run was performed to analyze the cell
purity of the sorted cells, sorted cells were always 498% pure.
In some experiments, CD4þCD25þ T cells were isolated using
negative CD4 selection combined with CD25þ magnetic-activated
cell sorting isolation (Miltenyi-Biotec) using half the amount of
beads as recommended by the manufacturer. Cells were cultured
as described previously (Koenen et al., 2008).
Reagents
Recombinant human cytokines IL-2 (12.5Uml1, Proleukine,
Amsterdam, the Netherlands), IL-15 (10 ngml1), IL-1b (50 ngml1;
Biosource, Etten-Leur, the Netherlands), and IL-23 (50 ngml1;
R&D-Systems, Abingdon, UK). TSA (Sigma, Zwijndrecht, the
Netherlands; 50 ngml1).
Flowcytometry and antibodies
Cells were analyzed by five to six color flowcytometry as described
previously (Koenen et al., 2008) using an FC500 or CyAn
flowcytometer (Beckman-Coulter). The following conjugated anti-
bodies were used: CD3(UCHT1), CD4(MT310), CD45RA(4KB5)
(Dako), CD25(M-A251), CD127(M21) (BD biosciences), CD4(T4)
(Beckman-Coulter). Intracellular analysis of Foxp3(259D/C7)AF647
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Figure 4. Ex vivo-stimulated CD4þ CD25high T cells from patients with severe psoriasis show a reduced number of Foxp3 expressing cells. (a) Flowcytometry
of intracellular Foxp3 expression in high-purity cell sorted CD4þCD45RA-CD25high from healthy controls (upper panel) and severe psoriasis patients (lower
panel) on stimulation as indicated at the top. Measurements were taken at day 8. Histograms show Foxp3 expression (x-axis) and number of events (y-axis).
Percentages of Foxp3-expressing cells are indicated in the histograms. Representative experiments from n¼ 6–7 controls or patients are shown. (b) Summarized
data showing the percentages of Foxp3 expressing (y-axis) in sorted and ex vivo-stimulated CD4þCD45RA-CD25high from healthy controls and severe psoriasis
patients as indicated in a. Each data point represents one separate experiment conducted with cells obtained from different healthy blood donors or severe
psoriasis patients. (c) Flowcytometry of intracellular Foxp3 and IL-17A expression in high-purity cell sorted CD4þ CD45RA-CD25high cells from healthy
controls (upper panels) and severe psoriasis patients (lower panels) on ex vivo stimulation as mentioned under a. (d) Stimulation of psoriasis patient-derived
Tregs in the absence or of presence Trichostatin-A (TSA). Dot plots show percentage of IL-17A-producing cells that are Foxp3 or Foxp3þ . Representative
experiments from n¼6–7 controls or patients are shown.
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(BD biosciences), Foxp3(PCH101)FITC, PE or pacific blue, RORg
t(AFKJS-9)PE or APC and IL-17A(6CAP17)PE of AF647 (eBioscience,
SanDiego, CA) was performed as described previously (Koenen
et al., 2008). Isotype-matched antibodies were used to define marker
settings.
T-cell proliferation and co-culture suppression assays
The proliferative capacity of isolated CD4þCD25þ or
CD4þCD25 T cells (5 104) was analyzed by 3H-thymidine
incorporation, as described previously (Koenen et al., 2008), after
stimulation with anti-CD3/CD28-coated beads (Invitrogen, Breda,
the Netherlands) with or without exogenously added recombinant
human IL-2 (12.5Uml1). The suppressor capacity of T cells
was studied in co-culture assays (Koenen et al., 2008). In brief,
CD4þCD25 (5 104) T cells were stimulated with anti-CD3/
CD28-coated beads in the absence and presence of decreasing
numbers of CD4þCD25þ or CD4þCD25 T cells. Cell prolifera-
tion was analyzed at day 4 of the cultures.
Cytokine measurement in cell culture supernatants
Cytokines were determined in the supernatant of the T-cell cultures
by Luminex cytokine assays (IL-17A, IFNg; Biorad, Veenendaal,
the Netherlands) and ELISA (IL-22; R&D-systems) according to the
manufacturer’s instructions.
Immunohistochemistry of skin biopsies
Tissue sections of 4–6 mm were generated after embedding the skin
biopsies in paraffin. Triple immunostainings were conducted
using anti-human primary antibodies: CD4 (BC/1F6; SantaCruz
Biotechnology, SantaCruz, CA), FoxP3(PCH101), and polyclonal
goat IL-17A (R&D-Systems). For the first immunostaining, antigens
were retrieved by boiling the sections in Tris/EDTA buffer (50mM
Tris, 2mM EDTA, pH 9.0) for 3minutes. After washing, sections were
incubated overnight with anti-FoxP3 antibody (1:100). To detect
Foxp3þ cells, the section were sequentially washed and incubated
(30minutes) with biotinylated anti-rat antibody (1:200; Vector
Laboratories, Burlingame, CA), avidin–biotin complex, horseradish
peroxidase solution (1:50; Vectastain ABC-elite kit; Vector Labora-
tories), and visualized using 3,30 diaminobenzidine. For the
second immunostaining, the sections were washed, pre-incubated
for 15minutes with 20% normal swine serum and incubated
overnight with anti-IL-17A antibody (1:500). To detect IL-17A-
producing cells, the section were stained using the Labeled
Streptavidin Biotin method (Universal LSABþ Kit/AP; Dako) and
visualized using Permanent Red (Dako). Finally, for the third
immunostaining, the sections were preincubated as described above
and incubated overnight with anti-CD4 antibody (1:100). CD4
expressing cells were detected by the LSAB method and visualized
using Vector Blue (Vector Laboratories). Sections were photographed
at an objective magnification of  20 or  40 using a microscope
(Axioskop2 MOT; Zeiss, Sliedrecht, the Netherlands), digital camera
(Axiocam MRc5; Zeiss) and AxioVision software (Zeiss).
Statistics
Results are presented as mean±SEM if not otherwise stated.
Analyses of variance and two-tailed t-tests were performed were
appropriate. Differences were considered significant at Po0.05.
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